188 related articles for article (PubMed ID: 36902115)
1. PT320, a Sustained-Release GLP-1 Receptor Agonist, Ameliorates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Kuo TT; Chen YH; Wang V; Huang EY; Ma KH; Greig NH; Jung J; Choi HI; Olson L; Hoffer BJ; Tseng KY
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902115
[TBL] [Abstract][Full Text] [Related]
2. Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
Tseng KY; Kuo TT; Wang V; Huang EY; Ma KH; Olson L; Hoffer BJ; Chen YH
J Parkinsons Dis; 2022; 12(5):1545-1565. PubMed ID: 35599497
[TBL] [Abstract][Full Text] [Related]
3. PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson's Disease.
Yu SJ; Chen S; Yang YY; Glotfelty EJ; Jung J; Kim HK; Choi HI; Choi DS; Hoffer BJ; Greig NH; Wang Y
Front Neurosci; 2020; 14():785. PubMed ID: 32848559
[TBL] [Abstract][Full Text] [Related]
4. Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease.
Wang V; Kuo TT; Huang EY; Ma KH; Chou YC; Fu ZY; Lai LW; Jung J; Choi HI; Choi DS; Li Y; Olson L; Greig NH; Hoffer BJ; Chen YH
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):858-869. PubMed ID: 33860208
[TBL] [Abstract][Full Text] [Related]
5. L-Dopa induced dyskinesias in Parkinsonian mice: Disease severity or L-Dopa history.
Shan L; Diaz O; Zhang Y; Ladenheim B; Cadet JL; Chiang YH; Olson L; Hoffer BJ; Bäckman CM
Brain Res; 2015 Aug; 1618():261-9. PubMed ID: 26086365
[TBL] [Abstract][Full Text] [Related]
6. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
7. Chronic L-DOPA induces hyperactivity, normalization of gait and dyskinetic behavior in MitoPark mice.
Gellhaar S; Marcellino D; Abrams MB; Galter D
Genes Brain Behav; 2015 Mar; 14(3):260-70. PubMed ID: 25752644
[TBL] [Abstract][Full Text] [Related]
8. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
9. Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice.
Wang V; Tseng KY; Kuo TT; Huang EY; Lan KL; Chen ZR; Ma KH; Greig NH; Jung J; Choi HI; Olson L; Hoffer BJ; Chen YH
J Biomed Sci; 2024 Apr; 31(1):38. PubMed ID: 38627765
[TBL] [Abstract][Full Text] [Related]
10. Nitric oxide synthase inhibition attenuates L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease.
Padovan-Neto FE; Echeverry MB; Tumas V; Del-Bel EA
Neuroscience; 2009 Mar; 159(3):927-35. PubMed ID: 19302833
[TBL] [Abstract][Full Text] [Related]
11. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia.
Ravenscroft P; Chalon S; Brotchie JM; Crossman AR
Exp Neurol; 2004 Jan; 185(1):36-46. PubMed ID: 14697317
[TBL] [Abstract][Full Text] [Related]
12. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
13. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia.
Lindgren HS; Andersson DR; Lagerkvist S; Nissbrandt H; Cenci MA
J Neurochem; 2010 Mar; 112(6):1465-76. PubMed ID: 20050978
[TBL] [Abstract][Full Text] [Related]
14. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
[TBL] [Abstract][Full Text] [Related]
15. Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease.
Pinna A; Ko WK; Costa G; Tronci E; Fidalgo C; Simola N; Li Q; Tabrizi MA; Bezard E; Carta M; Morelli M
Mov Disord; 2016 Apr; 31(4):501-11. PubMed ID: 26871939
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.
Kumar R; Riddle LR; Griffin SA; Chu W; Vangveravong S; Neisewander J; Mach RH; Luedtke RR
Neuropharmacology; 2009; 56(6-7):956-69. PubMed ID: 19371586
[TBL] [Abstract][Full Text] [Related]
17. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
18. Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Mango D; Bonito-Oliva A; Ledonne A; Cappellacci L; Petrelli R; Nisticò R; Berretta N; Fisone G; Mercuri NB
Exp Neurol; 2014 Nov; 261():733-43. PubMed ID: 25173217
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Lundblad M; Usiello A; Carta M; Håkansson K; Fisone G; Cenci MA
Exp Neurol; 2005 Jul; 194(1):66-75. PubMed ID: 15899244
[TBL] [Abstract][Full Text] [Related]
20. Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats.
Sgroi S; Capper-Loup C; Paganetti P; Kaelin-Lang A
Exp Neurol; 2016 Jun; 280():80-8. PubMed ID: 27072528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
